Discontinuation report CIPROFLOXACIN INJECTION USP
| Report ID | 170302 |
| Drug Identification Number | 02301903 |
| Brand name | CIPROFLOXACIN INJECTION USP |
| Common or Proper name | CIPROFLOXACIN INJECTION USP |
| Company Name | PFIZER CANADA ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | CIPROFLOXACIN |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 24 x 100mL bag |
| ATC code | J01MA |
| ATC description | QUINOLONE ANTIBACTERIALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2022-09-30 |
| Remaining supply date | 2022-09-30 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2022-10-01 | English | Compare |
| v2 | 2022-09-27 | French | Compare |
| v1 | 2022-09-27 | English | Compare |
Showing 1 to 3 of 3